Welcome to our dedicated page for Nephros news (Ticker: NEPH), a resource for investors and traders seeking the latest updates and insights on Nephros stock.
Nephros Inc. (Nasdaq: NEPH) is a commercial-stage medical device and water technology company dedicated to enhancing water quality in both medical and commercial markets. Founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center, Nephros initially aimed to address the needs of chronic renal failure patients. Today, the company is known for its innovative liquid purification filters that capture contaminants as small as 5 nanometers, significantly reducing exposure to a variety of pathogens, including bacteria, viruses, fungi, parasites, and endotoxins.
The heart of Nephros's technology lies in its proprietary hollow fiber design, which balances three critical elements for optimal filter performance: filtration precision, flow rate, and filter lifespan. These filters are highly efficient, providing up to 12 months of service with minimal disruption in flow rate, making them ideal for both healthcare and commercial applications.
In the medical sector, Nephros offers advanced water filtration products and waterborne pathogen detection tools. These products are essential for maintaining high standards of water safety, particularly in healthcare settings where water quality can directly impact patient outcomes. The company's subsidiary is actively working on a second-generation hemodiafiltration system and other devices aimed at improving therapies for renal disease patients.
In the commercial market, Nephros manufactures water filters designed to enhance the taste and odor of water, while also reducing biofilm, bacteria, and scale buildup in downstream equipment. These products cater to a wide range of industries, including hospitality, food service, and manufacturing, where water quality is a critical factor.
Nephros has recently achieved significant milestones, including:
- Filing its third-quarter financial results on November 8, 2023, with a subsequent conference call to discuss the outcomes.
- Hosting investor relations calls to keep stakeholders informed about company developments.
- Continued commitment to providing cutting-edge water filtration solutions and education to improve water safety.
With a mission to improve the human relationship with water, Nephros remains at the forefront of water technology innovation, offering proactive and emergency solutions to ensure water quality across various sectors. For more information, visit the company's website at Nephros.com.
Nephros (Nasdaq: NEPH) has acquired the assets of GenArraytion, Inc., a leader in infectious disease monitoring. This acquisition aims to enhance Nephros's capabilities in pathogen detection, leveraging GenArraytion’s Polymerase Chain Reaction (PCR) technology to advance their pathogen detection systems. Nephros expects this strategic move to solidify its position in the emerging PCR testing market, improve water safety measures, and provide quicker testing solutions for waterborne pathogens. The integration of technologies is anticipated to enhance customer service through accurate and actionable data.
Nephros, Inc. (NASDAQ: NEPH), a leading water technology company, announced its participation in the Access to Giving Virtual Investor Conference from July 13-15, 2021. CEO Andy Astor will present on July 13th at 2:30 PM ET, with a replay available post-event. The conference will feature over 50 companies focusing on investor education and financial literacy. Nephros aims to advance water safety through innovative solutions. For more details, visit their official site or register for the conference.
Nephros, Inc. (Nasdaq: NEPH) reported an anticipated net revenue of approximately $2.2 million for Q2 2021, marking over a 40% year-over-year increase. Year-to-date revenue exceeded $5 million, reflecting a 20% increase compared to the same period in 2020 and 2019. The company also submitted its HDF Assist Module for FDA 510(k) clearance and noted growing revenue in its Pathogen Detection Systems business segment. Nephros ended Q2 with around $8.3 million in cash, positioning itself well for the upcoming months.
Nephros, Inc. (Nasdaq: NEPH) reported its highest first-quarter revenue of $2.7 million, an increase of 8% compared to the same period last year. The net loss improved by 55% to $0.5 million, while adjusted EBITDA showed a 13% improvement, totaling ($0.7 million). The company attributes this growth to increased customer acquisition and recurring revenue, as healthcare facilities shift focus from COVID-19 to water management. Nephros had cash and equivalents of $8.2 million as of March 31, 2021, indicating a solid financial position.
Nephros, Inc. (Nasdaq: NEPH) announced it will release its first quarter financial results on May 6, 2021, after market close. A conference call is scheduled for the same day at 4:30 PM ET, allowing investors to engage with company executives. Participants can join by calling domestic number 1-844-808-7106 or international number 1-412-317-5285. A replay of the call will be available until May 13, 2021. Nephros specializes in water purification and pathogen detection, focusing on point-of-use water safety.
Nephros, Inc. (Nasdaq: NEPH) has reported a preliminary net revenue of $2.7 million for Q1 2021, marking a 17% increase from the previous quarter and an 8% rise compared to the same period in 2020. This achievement signifies the highest first-quarter revenue in the company's history and the third-highest quarterly revenue overall. The company ended the quarter with approximately $8.1 million in cash. Results are attributed to strong performance across filtration markets despite the pandemic, with expectations for further growth as vaccination progresses.
Nephros, a water technology company specializing in filtration and pathogen detection, announced that CEO Andy Astor will present at the Q1 Virtual Investor Summit from March 23-25, 2021. Nephros's presentation is scheduled for March 23 at 2:30 p.m. ET. Interested participants can register for the event and request one-on-one meetings via the conference's website. Nephros is dedicated to advancing water safety in medical and commercial markets by providing innovative solutions.
Nephros, a water technology leader, announced that CEO Andy Astor will present at the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. The event will showcase discussions with C-suite executives and feature insights into Nephros' advancements in water safety, including pathogen detection and purification technologies. The conference aims to connect thousands of issuers with investors through presentations and live Q&A sessions. For more details, visit www.nephros.com.
Nephros, Inc. (Nasdaq:NEPH) reported fourth-quarter 2020 net revenue of $2.3 million, a 26% decline from the previous year's $3.2 million. The full-year revenue dropped 17%, totaling $8.6 million compared to $10.3 million in 2019. The net loss for Q4 was approximately ($759,000), marking a significant increase from a net income of $234,000 in 2019. Adjusted EBITDA shows a loss of ($466,000) for Q4, in contrast to a profit of $374,000 a year earlier. Despite challenges due to COVID-19, the company's CEO expressed optimism for a return to growth in the latter half of 2021.
Nephros, Inc. (Nasdaq: NEPH), a water technology leader, will release its fourth quarter and full year 2020 financial results on March 1, 2021, after market close. A conference call is scheduled for the same day at 4:30 PM ET, where management will discuss the financial results and business outlook. Call-in details include a participant dial-in number and a replay option available until March 8, 2021. Nephros focuses on advancing water safety in medical and commercial sectors through innovative filtration and pathogen detection solutions.
FAQ
What is the current stock price of Nephros (NEPH)?
What is the market cap of Nephros (NEPH)?
What does Nephros Inc. specialize in?
When was Nephros Inc. founded?
What is the core technology of Nephros filters?
What markets does Nephros serve?
What recent achievements has Nephros announced?
How long do Nephros filters last?
How does Nephros contribute to water safety in medical settings?
What is mid-dilution hemodiafiltration (mid-HDF)?
Who are the key contacts for investor relations at Nephros?
Where can I find more information about Nephros?
